Health technology assessment and priority setting for universal health coverage: a qualitative study of stakeholders' capacity, needs, policy areas of demand and perspectives in Nigeria.


Journal

Globalization and health
ISSN: 1744-8603
Titre abrégé: Global Health
Pays: England
ID NLM: 101245734

Informations de publication

Date de publication:
08 07 2020
Historique:
received: 18 04 2020
accepted: 17 06 2020
entrez: 10 7 2020
pubmed: 10 7 2020
medline: 7 4 2021
Statut: epublish

Résumé

Health technology assessment (HTA) is an effective tool to support priority setting and generate evidence for decision making especially en route to achieving universal health coverage (UHC). We assessed the capacity needs, policy areas of demand, and perspectives of key stakeholders for evidence-informed decision making in Nigeria where HTA is still new. We surveyed 31 participants including decision makers, policy makers, academic researchers, civil society organizations, community-based organizations, development partners, health professional organizations. We revised an existing survey to qualitatively examine the need, policy areas of demand, and perspectives of stakeholders on HTA. We then analyzed responses and explored key themes. Most respondents were associated with organizations that generated or facilitated health services research. Research institutes highlighted their ability to provide expertise and skills for HTA research but some respondents noted a lack of human capacity for HTA. HTA was considered an important and valuable priority-setting tool with a key role in the design of health benefits packages, clinical guideline development, and service improvement. Public health programs, medicines and vaccines were the three main technology types that would especially benefit from the application of HTA. The perceived availability and accessibility of suitable local data to support HTA varied widely but was mostly considered inadequate and limited. Respondents needed evidence on health system financing, health service provision, burden of disease and noted a need for training support in research methodology, HTA and data management. The use of HTA by policymakers and communities in Nigeria is very limited mainly due to inadequate and insufficient capacity to produce and use HTA. Developing sustainable and institutionalized HTA systems requires in-country expertise and active participation from a range of stakeholders. Stakeholder participation in identifying HTA topics and conducting relevant research will enhance the use of HTA evidence produced for decision making. Therefore, the identified training needs for HTA and possible research topics should be considered a priority in establishing HTA for evidence-informed policy making for achieving UHC particularly among the most vulnerable people in Nigeria.

Identifiants

pubmed: 32641066
doi: 10.1186/s12992-020-00583-2
pii: 10.1186/s12992-020-00583-2
pmc: PMC7346669
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

58

Références

Value Health Reg Issues. 2016 May;9:78-83
pubmed: 27881265
J Med Assoc Thai. 2008 Jun;91 Suppl 2:S74-87
pubmed: 19253490
Int J Technol Assess Health Care. 2020 Apr;36(2):80-86
pubmed: 31402790
Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:241-52
pubmed: 19527543
Value Health. 2009 Nov-Dec;12 Suppl 3:S31-5
pubmed: 20586978
Int J Technol Assess Health Care. 2005 Winter;21(1):1-14
pubmed: 15736509
J Mark Access Health Policy. 2017 Aug 31;5(1):1335162
pubmed: 29785251
Bull World Health Organ. 2014 Jun 1;92(6):389
pubmed: 24940009
F1000Res. 2017 Mar 7;6:231
pubmed: 28721199
Health Res Policy Syst. 2018 Nov 29;16(1):115
pubmed: 30486827
Bull World Health Organ. 2016 Jun 1;94(6):462-7
pubmed: 27274598
Glob Heart. 2012 Mar;7(1):13-34
pubmed: 25691165
Int J Health Policy Manag. 2016 Jun 22;5(11):615-618
pubmed: 27801355
Int J Equity Health. 2018 Jul 11;17(1):100
pubmed: 29996838
Glob Health Action. 2015 Mar 03;8:26616
pubmed: 25739967
Niger Med J. 2014 Nov;55(6):519-20
pubmed: 25538375
PLoS Med. 2013 Aug;10(8):e1001495
pubmed: 23940462
Int J Technol Assess Health Care. 2000 Winter;16(1):73-91
pubmed: 10815355
Niger J Clin Pract. 2015 Jul-Aug;18(4):437-44
pubmed: 25966712
BMC Health Serv Res. 2009 Mar 05;9:43
pubmed: 19265518
Glob Health Action. 2017;10(1):1370194
pubmed: 29035166
Iran J Public Health. 2013 Jan 01;42(Supple1):50-4
pubmed: 23865016
BMJ. 2010 Jul 16;341:c3651
pubmed: 20639295
Cost Eff Resour Alloc. 2018 May 18;16:18
pubmed: 29796012
Value Health. 2020 Feb;23(2):171-179
pubmed: 32113622
F1000Res. 2017 Dec 11;6:2119
pubmed: 29333249
Health Res Policy Syst. 2020 Apr 28;18(1):41
pubmed: 32345297
Health Res Policy Syst. 2014 Dec 02;12:66
pubmed: 25466570
Appl Health Econ Health Policy. 2017 Feb;15(1):33-43
pubmed: 27637919
Natl Med J India. 2014 May-Jun;27(3):159-63
pubmed: 25668089
Value Health Reg Issues. 2013 Sep - Oct;2(2):264-266
pubmed: 29702875

Auteurs

Benjamin S C Uzochukwu (BSC)

Department of Community medicine, College of Medicine, University of Nigeria Enugu Campus Nigeria, Enugu, Nigeria.

Chinyere Okeke (C)

International Decision Support Initiative (iDSI), Global Health and Development Group, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, UK. chinyereokeke83@yahoo.com.

Niki O'Brien (N)

International Decision Support Initiative (iDSI), Global Health and Development Group, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, UK.

Francis Ruiz (F)

International Decision Support Initiative (iDSI), Global Health and Development Group, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, UK.

Issiaka Sombie (I)

West Africa Health Organisation, Organisation Ouest Africaine de la Santé, 175 avenue Ouezzin Coulibaly, Bobo-Dioulasso 01, 01 BP 153, Burkina Faso.

Samantha Hollingworth (S)

School of Pharmacy, University of Queensland, Wooloongabba, QLD, 4102, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH